Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in...

Area of Science:

• Neuroscience
• Neuropharmacology
• Neurodegenerative Diseases

Background:

• Group 1 metabotropic glutamate subtype 5 receptors (mGluR5) are crucial for motor control via basal ganglia pathways.
• Increased mGluR5 density is observed in Parkinson's disease (PD), suggesting a role in motor complications.

Purpose of the Study:

• To investigate mGluR5 density changes in Huntington's disease (HD), hypothesizing similar alterations as seen in PD.
• To examine the relationship between mGluR5 density and neuronal loss in postmortem HD brain tissue.

Main Methods:

• Autoradiography was used to quantify mGluR5 density in postmortem human putamen, caudate nucleus, and cerebellum from HD patients and controls, utilizing two specific radioligands.
• Immunohistochemistry and cell counting assessed the density of enkephalin (Enk)- and substance P (SP)-containing neurons.

Main Results:

• mGluR5 density was significantly reduced in the caudate nucleus (-70.4%) and putamen (-33.3%) of HD patients compared to controls.
• Neuronal density was markedly decreased in the caudate (69%) and putamen (64%) of HD patients, with over 90% reduction in Enk- and SP-containing neurons.
• Contrary to PD findings, HD brains showed decreased mGluR5 density, primarily attributed to significant neuronal loss.

Conclusions:

• Huntington's disease is characterized by a significant reduction in mGluR5 density, particularly in the striatum (caudate and putamen).
• The observed decrease in mGluR5 is largely explained by substantial neuronal loss in HD, differing from the receptor upregulation seen in Parkinson's disease.
• These findings highlight distinct neurochemical alterations in HD compared to PD, impacting basal ganglia function and motor control.